Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × prednisolone phosphate × Clear all
NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Ipsen

Phase 1/2 Completed
400 enrolled 22 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡